Stock Market News

Eli Lilly shares have more upside, claims Wells Fargo

Eli Lilly (LLY) shares have more upside, claims Wells Fargo


Wells Fargo’s analysts raised the firm’s price target on Eli Lilly & Co. (NYSE:LLY) to $500 from $440, maintaining an Overweight rating on the stock in a note Friday.

The analysts said the firm “would be owners of LLT” into competitor Novo’s SELECT trial reading out in mid-23.

“We think successful trial could move LLY up 5%, while failure could mean 10% downside,” said the analysts, who added that even though LLY shares have performed well in the last three months, they see more upside.

Eli Lilly shares are up more than 16% this year, while it has gained almost 40% in the last 12 months, currently trading around the $426.50 mark.

Wells Fargo stated their analysis indicates likely success in the SELECT trial based on the multiple benefits GLP-1 mechanism provides.


Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button